Evidence map›Paper›PMID 38805667›Full record

ArticleJournal of medicinal chemistry2024

Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders.

Peng Li, Qiang Zhang, Hailin Zheng, Yupu Qiao, Gretchen L Snyder, Terry Martin, Wei Yao, Lei Zhang, Robert E Davis

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Peng LiIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.ORCID 0000-0002-5347-4395
Qiang ZhangIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.
Hailin ZhengIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.
Yupu QiaoIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.
Gretchen L SnyderIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.
Terry MartinIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.
Wei YaoIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.
Lei ZhangIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.
Robert E DavisIntra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, New York 10016, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of more efficacious medications with improved safety profiles to manage and treat multiple forms of pain is a critical element of healthcare. To this end, we have designed and synthesized a novel class of tetracyclic pyridopyrroloquinoxalinone derivatives with analgesic properties. The receptor binding profiles and analgesic properties of these tetracyclic compounds were studied. Systematic optimizations of this novel scaffold culminated in the discovery of the clinical candidate, (6

Indexed as

AnalgesicsPainAdministration, OralAnimalsBiological AvailabilityDrug DiscoveryHumansMaleMicePyridinesPyrrolesRatsRats, Sprague-DawleyReceptors, Opioid, muStructure-Activity RelationshipAnalgesicsPyridinesPyrrolesReceptors, Opioid, mu

Identifiers

PMID38805667
PMCPMC11181336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.